News & Updates
Filter by Specialty:
Corticosteroids help prevent hearing loss, neurologic sequelae in paediatric bacterial meningitis
Children with bacterial meningitis appear to fare well with corticosteroids, which lead to a lower incidence of hearing loss and neurologic sequelae and faster resolution of fever, according to a meta-analysis.
Corticosteroids help prevent hearing loss, neurologic sequelae in paediatric bacterial meningitis
15 Mar 2022
Sofosbuvir easy on the kidneys
Use of sofosbuvir-based direct-acting antiviral regimens for treating hepatitis C virus (HCV) in clinical trial participants with chronic kidney disease (CKD) does not appear to worsen estimated glomerular filtration rate levels, according to a study. Furthermore, the drug does not appear to contribute to an increased risk of end-stage renal disease among HCV patients with CKD treated in clinical practice.
Sofosbuvir easy on the kidneys
15 Mar 2022
People who trust formal information source more likely to get COVID-19 jab
Among middle-aged and older adults, trust in formal sources of vaccine information, such as government agencies, is a strong predictor of willingness to get vaccinated against the coronavirus disease 2019 (COVID-19), according to a recent Singapore study.
People who trust formal information source more likely to get COVID-19 jab
14 Mar 2022
Vitamin D deficiency tied to severe COVID-19
A systematic review and meta-analysis of >8,000 adult and elderly patients with COVID-19 showed a positive association between vitamin D deficiency (ie, 25(OH)D <50 nmol/L) and severe COVID-19.
Vitamin D deficiency tied to severe COVID-19
13 Mar 2022
Record-high rise in alcohol-related hepatitis during pandemic a cause for alarm
Cases of severe alcohol-related hepatitis requiring inpatient management has dramatically increased during the COVID-19 pandemic, particularly in patients aged <40 years and in women, a study has found.
Record-high rise in alcohol-related hepatitis during pandemic a cause for alarm
12 Mar 2022
Shorter antibiotic regimen enough in kids with pneumonia?
Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.